Alpha 2.0
Login Register
» Articles » PMID: 34384312

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2021 Aug 13
PMID 34384312
Citations 3
Authors
Jennifer Woyach
Alessandra Tedeschi
Talha Munir
Tanya Siddiqi
Peter Hillmen
John C Byrd
Paolo Ghia
Stephen P Mulligan
Sandra Dai
Carlos I Amaya-Chanaga
James P Dean
Susan M OBrien
Paul M Barr
Affiliations
Soon will be listed here.
Citing Articles

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.

Woyach J, Ghia P, Byrd J, Ahn I, Moreno C, OBrien S Clin Cancer Res. 2023; 29(16):3065-3073.

PMID: 37314786 PMC: 10425728. DOI: 10.1158/1078-0432.CCR-22-3887.

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.

Omi A, Nomura F, Tsujioka S, Fujino A, Akizuki R J Clin Exp Hematop. 2022; 62(3):136-146.

PMID: 35831100 PMC: 9635026. DOI: 10.3960/jslrt.22002.

Upfront therapy: the case for continuous treatment.

Tam C Hematology Am Soc Hematol Educ Program. 2021; 2021(1):55-58.

PMID: 34889433 PMC: 8791150. DOI: 10.1182/hematology.2021000232.